Abstract
From January to September 2024, a national active case-finding program in Peru’s prisons screened more than 38,000 incarcerated persons for tuberculosis using chest radiography with automated interpretation and rapid molecular diagnostics, yielding a tuberculosis prevalence of 2,800 per 100,000 persons, with 11.4% of cases rifampicin-resistant; 42.5% of cases were subclinical.
Article Summary Line A recent, nationwide mass screening program in Peru’s prisons using digital radiography with automated interpretation and molecular testing identified high tuberculosis prevalence and rates of rifampicin resistance, highlighting the need for active case-finding as an efficient strategy to identify undiagnosed TB burden in high-risk populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Stanford University waived ethical approval for this work. The IRB has determined that this research does not involve human subjects.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the Peruvian National TB Program.
